Recently, SAL0120 tablets， an innovative small molecule independently developed by Salubris, has been approved by NMPA to carry out clinical trial for the treatment of IgA nephropathy.
SAL0120 is a small molecule ETA receptor antagonist independently developed by Salubris, which is intended to be developed for indications including IgA nephropathy and mild to moderate primary hypertension. Phase I clinical trials are currently underway.
ETA receptor antagonist for the treatment of hypertension further emphasizes on target selectively, which is expected to play a role in the protection of heart and kidney while reducing blood pressure. In addition, ETA receptor antagonist is currently an important target in the treatment of IgA nephropathy, and anticipated to become a new therapy to improve the progression of IgA nephropathy.
If SAL0120 were successfully developed and approved for marketing, it would provide new options for patients with primary hypertension and IgA nephropathy, meet unmet clinical needs, and further enrich the company's innovative product pipeline in the field of chronic disease, therefore enhancing the company's core competitiveness.